3,042 reports of this reaction
1.6% of all BUPRENORPHINE reports
#12 most reported adverse reaction
APPLICATION SITE RASH is the #12 most commonly reported adverse reaction for BUPRENORPHINE, manufactured by Purdue Pharma LP. There are 3,042 FDA adverse event reports linking BUPRENORPHINE to APPLICATION SITE RASH. This represents approximately 1.6% of all 185,849 adverse event reports for this drug.
Patients taking BUPRENORPHINE who experience application site rash should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
APPLICATION SITE RASH is a less commonly reported adverse event for BUPRENORPHINE, but still significant enough to appear in the safety profile.
In addition to application site rash, the following adverse reactions have been reported for BUPRENORPHINE:
The following drugs have also been linked to application site rash in FDA adverse event reports:
APPLICATION SITE RASH has been reported as an adverse event in 3,042 FDA reports for BUPRENORPHINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
APPLICATION SITE RASH accounts for approximately 1.6% of all adverse event reports for BUPRENORPHINE, making it a notable side effect.
If you experience application site rash while taking BUPRENORPHINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.